Provectus Biopharmaceuticals, Inc.
PVCT
$0.05
$0.00-0.75%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 25.04% | -3.96% | -14.76% | -119.02% | -127.10% |
| Total Depreciation and Amortization | -45.95% | -62.96% | -71.83% | -77.27% | -57.95% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -34.59% | -23.84% | -6.71% | 4,553.85% | 3,724.44% |
| Change in Net Operating Assets | -19.63% | 305.97% | 524.37% | 2,632.49% | 436.10% |
| Cash from Operations | 21.60% | 22.29% | -1.28% | -14.83% | 1.39% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 45.25% | 2.14% | -12.02% | -18.72% | -20.73% |
| Total Debt Repaid | 6.74% | 9.63% | 32.61% | 36.77% | 27.38% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -77.50% | -77.50% | 183.33% | -- | -- |
| Cash from Financing | 8.37% | -22.90% | 12.34% | 30.82% | 22.23% |
| Foreign Exchange rate Adjustments | 400.00% | 900.00% | 175.00% | 98.31% | 100.45% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 528.22% | 16.29% | 55.59% | 31.93% | 77.54% |